Mutant VAPB: Culprit or Innocent Bystander of Amyotrophic Lateral Sclerosis?

Nica Borgese¹, Francesca Navone¹, Nobuyuki Nukina², and Tomoyuki Yamanaka²

Abstract
Nearly twenty years ago a mutation in the VAPB gene, resulting in a proline to serine substitution (p.P56S), was identified as the cause of a rare, slowly progressing, familial form of the motor neuron degenerative disease Amyotrophic Lateral Sclerosis (ALS). Since then, progress in unravelling the mechanistic basis of this mutation has proceeded in parallel with research on the VAP proteins and on their role in establishing membrane contact sites between the ER and other organelles. Analysis of the literature on cellular and animal models reviewed here supports the conclusion that P56S-VAPB, which is aggregation-prone, non-functional and unstable, is expressed at levels that are insufficient to support toxic gain-of-function or dominant negative effects within motor neurons. Instead, insufficient levels of the product of the single wild-type allele appear to be required for pathological effects, and may be the main driver of the disease. In light of the multiple interactions of the VAP proteins, we address the consequences of specific VAPB depletion and highlight various affected processes that could contribute to motor neuron degeneration. In the future, distinction of specific roles of each of the two VAP paralogues should help to further elucidate the basis of p.P56S familial ALS, as well as of other more common forms of the disease.

Keywords
endoplasmic reticulum (ER), intracellular inclusions, neurodegeneration, motor neuron, membrane contact sites, phosphoinositide

Introduction: Amyotrophic Lateral Sclerosis and VAPB
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of the human motor system, characterized by the degeneration of motor neurons (MNs) in the cerebral cortex, brain stem and spinal cord. Since these neurons regulate the function of skeletal muscles to control essential voluntary movements, their progressive loss leads to peripheral and/or central paralysis, loss of muscle mass (amyotrophy) and death within a few years of onset. Although motor manifestations are the main clinical manifestations of ALS, up to half of patients have non-motor symptoms, such as cognitive impairment (Brown and Al-Chalabi, 2017; Hardiman et al., 2017). An adulthood disease with middle to late age onset, ALS appears in both inherited and sporadic forms, often clinically indistinguishable. Only about 10% of ALS cases have a familial background (fALS), while the vast majority of them shows no apparent history of the disorder in families and, thus, are classified as sporadic (sALS).

The familial forms of ALS have been linked to a myriad of distinct genes. Indeed, since the discovery in 1993 of the first causative gene, the one coding for Cu/Zn superoxide dismutase (SOD1) (Rosen et al., 1993), more than 50 others associated with disease pathogenesis and...
susceptibility have been identified (Al-Chalabi et al., 2017; Brenner and Weishaupt, 2019), and research continues to uncover at an incredibly rapid pace novel monogenic disease genes, genetic risk factors, as well as disease-modifying genes. Due to the extremely heterogeneous and complex genetic architecture of ALS, the distinction between fALS and sALS is often blurred, the etiology of the disease not yet clearly defined for most patients and, as a consequence, effective treatments remain elusive (Morello et al., 2020). Nevertheless, the discovery and investigation of genetic forms of ALS has provided and continuously provides paramount information about the molecular mechanisms that cause MN death in ALS. More specifically, studies of ALS genes have given insight into the pathogenic roles of perturbations in protein homeostasis, altered RNA metabolism and DNA-repair, impaired membrane trafficking, axonal transport and cytoskeleton function (Mejzini et al., 2019).

One example of how the characterization of specific pathways and biological processes affected by ALS-linked genes in fALS has improved understanding of ALS pathogenesis, has been that of the VAPB (Vesicle-Associated Membrane Protein (VAMP)-Associated Protein B) - coding gene, situated at locus 20q13.3. VAPB is a member of a small family of adaptor proteins - the VAP proteins - localized at the Endoplasmic Reticulum (ER) (Nishimura et al., 1999; Murphy and Levine, 2016). Table 1 summarizes the main characteristics of different VAPB mutations detected in ALS patients.

A first missense mutation in the VAPB gene, consisting in a transition from C to T in exon 2 and resulting in substitution of proline 56 (within the Major Sperm Protein (MSP) domain - see “The VAPs: Structure and Functions” section) with serine (p.P56S), was originally identified in ALS patients in seven white Brazilian families (Nishimura et al., 2004b). The mutation is responsible for the autosomal dominantly inherited, atypical form of fALS, designated ALS type 8 (ALS8), characterised by slow progression, fasciculation, postural tremor, incapacitating cramps, and the preferential involvement of lower MNs (Nishimura et al., 2004a, 2004b). Additionally, the mutation is linked to other MN diseases, as some subjects were diagnosed with typical severe rapidly progressing ALS or with late-onset spinal muscular atrophy (Nishimura et al., 2004b; Marques et al., 2006). Linkage analysis carried out on four generations of the affected Brazilian families suggested that the mutation was inherited from a single founder living in the mid 15th century in Portugal, from where it was brought to Brazil during the colonial period and subsequently propagated through 23 generations (Nishimura et al., 2005). Although prevalence of the p.P56S mutation is high among Brazilian fALS patients (Chadi et al., 2017), it is very rare elsewhere.
(<1%) (Connolly et al., 2020); outside of Brazil it has been observed in a family of Japanese descent (Millecamps et al., 2010), in a German family, affected by late onset SMA and other dominant MNDs (Funke et al., 2010), in a North American patient (Guber et al., 2018), as well as in a Chinese family, the latter with different clinical manifestations, including signs of autonomic nervous system impairment (Di et al., 2016). In both the German patient and in the Chinese families, haplotype analysis revealed that the p.P56S mutation had arisen independently from the Brazilian cohort. Interestingly, a novel mutation at position 56 (p.P56H) was discovered in one Chinese fALS pedigree (Sun et al., 2017), with the affected patients showing similar clinical features, though with a slower disease progression than the more common p.P56S mutation.

In addition to the substitutions at position P56, three further missense mutations have been described at other positions of the VAPB sequence in single ALS patients and not in controls (p.T46I, p.V234I, and p.A145V). T46, like P56, lies within the MSP domain, V234 is in the transmembrane (TM) helix, and A145 is in the cytosolic region between the MSP and the TM domains (see Figure 1 and “The VAPs: Structure and Functions” section). At variance with the p.P56S and p.P56H mutations, it has not been possible to demonstrate segregation of these three mutations with the disease, because of the unavailability of DNA samples from family members. However, both p.T46I and p.V234I, discovered in fALS patients, result in structurally and/or functionally abnormal proteins in cell and animal models (references in Table 1). The possible pathogenicity of the p.A145V mutation, identified in a sALS patient, has been less investigated.

In this review we will discuss possible pathogenic mechanisms of the best characterized, p.P56S, VAPB mutation. We will limit our discussion to the cell-autonomous roles of the VAPs, and will not address possible extracellular effects of cleaved VAPB fragments, a phenomenon studied mainly in invertebrates (Tsuda et al., 2008). After an overview of the manifold functions of the versatile VAP proteins, we will review the results of cellular, animal, and patient studies on mutant VAPB, focussing on possible mechanisms of its dominant inheritance, as well as on how its loss of function could affect MN survival.

**The VAPs: Structure and Functions**

VAPs are ubiquitously expressed ER resident tail-anchored transmembrane (TM) proteins composed of an N-terminal MSP domain that faces the cytosol, followed by a predicted coiled coil (CC) region, and C-terminal TM helix (Figure 1(a)). The MSP domain is so-named because of its homology to the most abundant nematode sperm proteins, which function both in cell locomotion and as extracellular signalling molecules (Miller et al., 2001; Bottino et al., 2002). The VAPs are evolutionarily conserved from yeast to mammals, and remarkable conservation of the MSP domain is observed among different species (Figure 1(b)), highlighting the significance of this domain for VAP functions (reviewed in Lev et al., 2008; Murphy and Levine, 2016; Dudas et al., 2021).

The first member of the family, VAP33, was identified as an interacting partner of the SNARE protein VAMP in nerve terminals of *Aplysia californica* (Skehel et al., 1995); hence it was named VAMP-associated protein (VAP) of 33 kDa. It was later demonstrated that mammalian VAP can unselectively bind numerous proteins of the SNARE family (Weir et al., 2001), however, the functional relevance of these interactions has not been elucidated so far.

Mammals express two VAPs, VAPA and VAPB, which share 82% identity in the MSP domain (Figure 1(a) and (b)). Splicing variants of VAPB have been identified at the mRNA level, however, the translation products of these transcripts have not been detected in tissues (Nishimura et al., 1999; Nachreiner et al., 2010). Recently three additional mammalian ER proteins that harbour an MSP domain have been identified and named motile sperm domain-containing proteins (MOSPD) 1-3, thus expanding the mammalian VAP family to five members (Di Mattia et al., 2018; Cabukusta et al., 2020).

VAPA and B are both able to form homodimers and also to heterodimerize with each other, a process driven by interactions between the TM helices (Nishimura et al., 1999; Kanekura et al., 2006), which both contain a dimerization motif (GXXXG; Russ and Engelman, 2000). The CC regions are also involved in dimerization (Kim et al., 2010), whereas the MSP domains, unlike the nematode homologs, are monomeric in solution (Kaiser et al., 2005; Shi et al., 2010). Dimerization may allow high avidity bivalent interactions of VAP with some of its ligands and/or bring different VAP ligands in close proximity to each other.

The VAPs function as adaptors, recruiting a myriad of binding partners to the cytosolic surface of the ER. This recruitment is often mediated by the binding of a so-called FFAT (two phenylalanines in an acidic tract) motif (consensus sequence: EFFDAXE) in the ligand to VAP’s MSP domain (Loewen et al., 2003). Extensive research aimed at identifying and characterizing VAP binding partners (the VAPome) has revealed that deviations from this motif are tolerated, leading to a bewildering expansion of potential VAP interactors (Murphy and Levine, 2016; Slee and Levine, 2019), and to an increased need to experimentally verify predicted interactions as well as to define additional features of VAP
ligands that strengthen their binding and confer selectivity for different MSPs (Furuita et al., 2010; Cabukusta et al., 2020). To be noted, FFAT motifs are not present in all cytosolic VAP binding partners, which may interact with regions of the MSP domain distinct from the FFAT binding site. In addition, the VAPs engage in functionally relevant interactions with ER membrane proteins via their TM helices (see “VAP Interactions in the ER” section below).

Structural studies have revealed the basis for the interaction of FFAT motifs with the VAP MSP domain, which is characterized by an immunoglobulin-like fold based on a seven-stranded β sandwich and one α helix. The FFAT binding site within the MSP consists of a conserved electropositive surface running transversally across four of the seven β strands, and two hydrophobic pockets that accommodate the second and fifth residue of the consensus (Figure 1 (c); Kaiser et al., 2005; Furuita et al., 2010; Shi et al., 2010).

Many FFAT-bearing VAP ligands engage in additional interactions with partners, which are often specific lipids, exposed on the cytosolic face of membrane-bounded organelles other than the ER, and can thus serve as bridges between the ER and these other compartments. Indeed, the VAPs are involved in the
generation of the majority of ER membrane contact sites (MCSs), key structures for interorganellar communication and integration (reviewed in Phillips and Voeltz, 2016; Prinz et al., 2020).

In the following paragraphs, and in Figure 2, we summarize the main VAP functions, identified up till now. The necessarily incomplete account is intended to provide a framework for the subsequent discussion of the cellular basis of the pathology caused by the p.P56S VAPB mutation.

**Lipid Transfer**

Numerous FFAT-containing VAP-interacting partners are Lipid Transfer Proteins (LTPs), which exchange single, or a small number of, lipid molecules between the ER, where most are synthesized, and other organelles, thereby regulating the intracellular distribution of diverse lipid species and playing key roles in generating and maintaining the molecular identity of organelles (reviewed in Wong et al., 2018).

Among the mammalian LTPs, oxysterol-binding protein (OSBP) was first identified as a binding partner of VAPA (Wyles et al., 2002), a finding subsequently extended to a number of OSBP-related proteins (ORPs), and leading to the identification of the FFAT binding motif (Loewen et al., 2003). Although OSBP was first identified as an oxysterol-binding protein, it was later demonstrated to couple cholesterol export from the ER to the Golgi with the transport of phosphatidylinositol-4-phosphate (PI4P) in the opposite direction (Mesmin et al., 2013). At contact sites between the ER and the trans-most Golgi cisternae (Ladinsky et al., 1999), OSBP binds VAP on ER membranes, and phosphatidylinositol-4-phosphate (PI4P) in combination with the small GTPase Arf1 at the Golgi (Levine and Munro, 2002). OSBP regulates PI4P levels also in endosomes and lysosomes, acting at contact sites between the ER and these organelles (Dong et al., 2016; Lim et al., 2019).

Other FFAT-containing, VAP-interacting, LTPs, listed in Figure 2, effect non-vesicular transfer from the ER of sphingolipids (Kawano et al., 2006; D’Angelo et al., 2007; Mititova and Levine, 2012) and glycerophospholipids (Kumar et al., 2018; Guillen-Samander et al., 2021), among which phosphatidylinositol (PI) (Kim et al., 2015; Cockcroft and Lev, 2021), and regulate the back-transport of cholesterol from the lysosomal/late endosome (LE) compartment to the ER (Alpy et al., 2013).

**Calcium Regulation**

Because of the VAP’s pivotal role in phosphoinositide metabolism and because of the role of this lipid class in Ca$^{2+}$ signalling, the VAPs are important players in many Ca$^{2+}$ dependent pathways (Balla et al., 2020). In addition, direct protein-protein interactions may mediate VAP’s role in regulating cytosolic [Ca$^{2+}$] and Ca$^{2+}$ stores. For example, the interaction between VAP and the outer mitochondrial membrane protein, protein tyrosine phosphatase-interacting protein 51 (PTPIP51) is critical for establishment of ER-mitochondria contacts and for the uptake of Ca$^{2+}$ by mitochondria following its release from ER stores (De Vos et al., 2012; Stoica et al., 2014). The molecular basis of the interaction of

**Figure 2.** Summary of the functions of the VAP proteins. See text for further explanation.
PTPIP51 with VAP has not been fully elucidated so far: a functional FFAT-like motif is present in the central part of the sequence (Mikitova and Levine, 2012; Cabukusta et al., 2020; Yamanaka et al., 2020), however VAP regions outside of the MSP also contribute to the binding (Stoica et al., 2014). Notably, however, the VAP-PTPIP51 interaction is affected by TDP-43 and α-Synuclein intracellular aggregates, which are associated with ALS and Parkinson’s disease, respectively (Stoica et al., 2014; Paillusson et al., 2017). These pathological aggregates perturb the ER-mitochondria association, in parallel with the disruption of Ca$^{2+}$ exchange between the two organelles.

An additional role of the VAPs in Ca$^{2+}$ signalling has been recently demonstrated in neurons, at presynaptic sites, where VAP interacts with the cytosolic protein Secernin-1 (SCRN1) via a FFAT-like motif. This interaction modulates ER dynamics and is required for the integrity of the organelle at nerve terminals; its loss results in alterations in presynaptic Ca$^{2+}$ regulation and synaptic vesicle cycling (Lindhout et al., 2019).

**Organelle Integrity and Dynamics**

Through their multiple interactions, the VAPs affect the morphology and dynamics of the organelles that they contact. Such effects may be mediated by the LTPs, with which VAPs interact, including OSBP at endosomes (Dong et al., 2016), and the glycerophospholipid LTPs VPS13A and D at ER-mitochondria and ER-lipid droplet contact sites (Kumar et al., 2018; Yeshaw et al., 2019; Guillen-Samander et al., 2021). In other cases, direct interactions between the VAPs and integral membrane proteins exposed on the surface of interacting organelles are involved. For instance, the VAPs bind the peroxisome membrane protein, acyl-coenzyme A-binding domain protein 5 (ACBD5), and the resulting tethering is critical for restriction of peroxisome motility, while it enhances membrane expansion and peroxisome growth (Costello et al., 2017; Hua et al., 2017). Regulation of organelle motility by VAP is observed also for the lysosome/LE compartment: the direct, cholesterol-regulated interaction of VAP with ORP1L, by preventing the interaction of lysosomes/LEs with the dynein-dynactin complex, blunts their microtubule-dependent, centripetal transport (Rocha et al., 2009). At the same time, VAP facilitates kinesin-dependent transport of endosomal vesicles towards the periphery (see “VAP Interactions in the ER” section, below).

Finally, at the neuronal plasma membrane, the voltage sensitive K$^+$ channel Kv2.1 interacts with VAP via a phosphorylated C-terminal FFAT-like motif; the interaction determines clustering of the channels at ER-plasma membrane contacts and also facilitates recruitment to the plasma membrane of the VAP-interacting Nir2/3 PI transfer proteins; these help to return the plasma membrane phospholipid composition to basal values after activation of signalling cascades (Johnson et al., 2018; Kirmiz et al., 2018).

**Autophagy**

VAP regulates several steps of autophagic processes. VAP (A+B) directly interacts with multiple autophagy proteins, thereby contributing to formation of ER-isolation membrane contacts and autophagosome biogenesis (Zhao et al., 2018). At a later step, the cholesterol-regulated interaction of VAP with the aforementioned ORP1L (“Organelle Integrity and Dynamics” section) on the lysosome/LE membrane, regulates their fusion with autophagosomes (Wijdeven et al., 2016). In addition, ER-mitochondria tethering by the VAPB-PTPIP51 interaction reduces autophagosome formation; delivery of Ca$^{2+}$ to mitochondria from ER stores, as well as transcriptional responses, appear to be involved in this phenomenon (Gomez-Suaga et al., 2017; Wu et al., 2018).

The size of the ER compartment itself is known to be regulated by a selective form of autophagy called ER-phagy. Several ER membrane proteins have been identified as receptors that mediate interaction of the ER with autophagy-related proteins of the ATG8/LC3 family (reviewed in Wilkinson, 2020). Recently, a cytosolic protein CALCOCO1 was also identified as an additional ER-phagy receptor, and in this case, its binding to VAP via the FFAT motif is critical for its role in promoting ER degradation (Nthiga et al., 2020).

**VAP Interactions in the ER**

In addition to their connections with membrane proteins of other organelles and with cytosolic proteins that serve as interorganellar bridges, the VAPs also engage in functionally important interactions with ER-resident proteins. These interactions may be mediated by FFAT motifs in the ligand, or may occur within the bilayer via interaction between the TM helices of the VAPs and the interacting protein. As illustrated below, some of these interactions appear to be particularly important in neurons.

**Neurite extension involving the VAP-protrudin interaction.** Protrudin is an ER membrane protein that bears a FFAT-like motif and binds the microtubule motor kinesin. It interacts with LEs by coincidence detection of the small GTPase Rab7 and Phosphatidylinositol-3-phosphate (Raiborg et al., 2015). This allows the hand-over of kinesin to the LEs and drives their transport towards the periphery, a process that provides the membrane required for neurite elongation. Since protrudin is an integral membrane protein, VAP is not required for
its localization to the ER. Nonetheless, VAPA binds protrudin \textit{via} the FFAT motif and is required for protrudin’s function in promoting neurite elongation (Saita et al., 2009). Notably, VAPA binds protrudin much more strongly than does VAPB, providing one of the few examples of different roles of the two paralogues.

\textbf{ER-to-Golgi transport and neurite extension involving YIF1A.} Yip1-interacting factor homologue A (YIF1A) is a transmembrane protein that recycles between the ER and Golgi, and that facilitates secretory transport from the ER to the Golgi in neurons, enhancing the generation of COPII-coated transport vesicles by an incompletely understood mechanism. The VAP-YIF1A interaction, mediated by the TM domains of the two proteins, appears to be functionally relevant: in cultured hippocampal neurons VAP depletion results in displacement of YIF1A from the ER to the ER-Golgi intermediate and \textit{cis} Golgi compartments, implicating that its recycling at the ER-Golgi interface is disturbed; the altered recycling correlates with a delayed transport of membrane vesicles into neurites, an effect caused also by YIF1A depletion, and which results in reduced dendrite extension and axon growth (Kuijpers et al., 2013b).

\textbf{Phosphoinositide phosphatase Sac1 and phosphoinositide regulation.} The ER-localized transmembrane protein Sac1 converts PI4P to PI, thereby regulating the levels of this phosphoinositide, a prominent player in lipid exchange at MCSs (“Lipid Transfer” section), in membrane trafficking and in cytoskeletal dynamics (Hammond and Burke, 2020). In \textit{Drosophila}, the single VAP ortholog, Vps33, binds Sac1 \textit{via} interaction between the TM domains and appears to be required for Sac1’s hydrolytic activity (Forrest et al., 2013). The interaction of the VAPs with Sac1 is also observed in yeast (Stefan et al., 2011) and in mammals (Wakana et al., 2015), where, as in the case of protrudin, VAPA is the preferred partner.

\textbf{Hyperpolarization-activated cyclic nucleotide–gated (HCN) channels 1 and 2.} The HCN cationic channels regulate rhythmic activity in the heart and in neuronal circuits, as well as synaptic transmission and neuronal excitability (Ludwig et al., 1998). The VAPs associate with HCN1 and 2 \textit{via} TM domain-mediated interactions, probably in the ER. The association appears to favour transport of these channels to the cell surface, with consequences for heartbeat rhythm as well as for neuronal excitability (Silbermagel et al., 2018).

\textbf{ATF6, FAF1 and the Unfolded Protein Response (UPR).} The VAPs have been implicated in the regulation of proteostasis and of the UPR, although different conclusions have been reached in different experimental models. Two described protein-protein interactions could contribute to VAP’s role in these processes: one that involves the UPR sensor/transcriptional regulator ATF6 (Gkogkas et al., 2008) and the other the p97 adaptor FAF1/UBXN3A/UBXD12 (Baron et al., 2014). ATF6 interacts with VAP’s MSP \textit{via} an unidentified portion of its N-terminal, cytosolic domain; the interaction, by blunting ATF6’s transcriptional activity, is thought to negatively regulate this arm of the UPR. The FAF1 adaptor belongs to a family of ubiquitin-binding adaptors for p97/Valosin Containing Protein (VCP), an AAA ATPase that, by extracting misfolded proteins from the ER for proteasomal degradation, is a central player in the ER Associated Degradation pathway (ERAD) (reviewed in Qi et al., 2017). Through the interaction with FAF1, mediated by a non-canonical FFAT motif, VAP is suggested to be recruited to a complex of proteins that mediate the ERAD pathway and to negatively regulate their activity (Ernst et al., 2016).

\section*{Possible Mechanisms for the Dominance of the p.P56S-VAPB Allele: Gain Versus Loss of Function}

Whereas haplosufficiency, i.e., sufficiency of the product of one wild-type allele for normal function, is the single cause of the recessive inheritance of many diseases, different, often not mutually exclusive, mechanisms underlie the phenotypic effects of dominant mutations (Wilkie, 1994). These can be roughly classified as gain-of-function mutations, meaning that the mutant protein acquires a new, generally harmful, function not possessed by its wild-type counterpart, or loss-of-function, meaning that the functionality of the product of the single wild-type allele is reduced or insufficient in the heterozygote. As mentioned in “Introduction: Amyotrophic Lateral Sclerosis and VAPB” section, the P56S-VAPB phenotype is dominantly inherited, and a number of possible mechanisms for this mode of transmission are conceivable, as schematized in Figure 3.

P56S-VAPB, when transfected into cultured cells or expressed in some model organisms, forms intracellular aggregates (Nishimura et al., 2004b; Tsuda et al., 2008; Fasana et al., 2010 - discussed in more detail in “The Intracellular Inclusions Formed by P56S-VAPB” section]. Because intracellular inclusions are hallmarks of neurodegenerative diseases, including ALS (Blokhuis et al., 2013), and because large aggregates or smaller oligomers of mutant proteins are the suspected culprits of many of these pathologies (Haass and Selkoe, 2007), much work has focussed on the possible role of the P56S-VAPB inclusions in ALS8 pathogenesis. \textit{A priori}, it could be hypothesized that the mutant protein is endowed with a gain of toxic function, because the intracellular inclusions that it generates could unphysiologically trap key proteins involved in pathways essential for cell survival (Powers et al., 2009; Olzschka et al., 2011), and/or lead to the accumulation of reactive oxygen...
species, thereby inflicting oxidative damage to cellular macromolecules (Barber et al., 2006). In addition, the binding by the inclusion-localized mutant VAPB to any of its numerous physiological interaction partners in a way that would not occur under normal conditions, should also be classified as gain-of-function. Instead, sequestration by the inclusions of the product of the wild-type VAPB allele would lead to loss-of-function by a classical mechanism of negative dominance. Additionally, loss-of function caused by haploinsufficiency could underlie the dominance of the p.P56S mutation. Haploinsufficiency, i.e., the intolerance of a diploid organism to the loss of one functional allele, occurs in the case of dosage-dependent genes, whose products, under physiological conditions, operate at levels close to the threshold for normal function (Wilkie, 1994; Johnson et al., 2019). It is the causal factor of a number of dominantly inherited diseases (Johnson et al., 2019), and contributes, for instance, to the pathogenic mechanism of the ALS-linked genes, C9ORF72 (Shi et al., 2018) and TBK1 (Freischmidt et al., 2015).

We have presented the above summary as a premise to the following sections of this review, in which we will discuss the evidence in support of, or against, each of the possible pathogenic mechanisms of the p.P56S mutation.

The Intracellular Inclusions Formed by P56S-VAPB

Concurrently with the pedigree analysis of the p.P56S mutation in Brazilian families, in vitro studies revealed that, differently from the wild-type protein, P56S-VAPB expressed in mammalian cultured cells clusters into large aggregates that can be detected by immunofluorescence (Nishimura et al., 2004b). The presence of such intracellular inclusions was subsequently confirmed both in transfected cells (Figure 4(a); Kanekura et al., 2006; Teuling et al., 2007; Prosser et al., 2008; Suzuki et al., 2009; Fasana et al., 2010; Papiani et al., 2012) and in transgenic animals (see Table 2 for references) and correlated well with the biochemical experiments showing the insolubility of mutant VAPB in neutral detergents. Further analysis revealed that, while the P56S substitution in the MSP is required for aggregation, the CC domain as well as the TM bearing the GXXXG dimerization motif are essential contributing factors (Kim et al., 2010).

Although it was initially anticipated that the P56S-VAPB inclusions would share features with other mutant protein aggregates involved in neurodegenerative diseases (reviewed in Chung et al., 2018), biochemical and high resolution morphological analyses revealed that, differently from other investigated pathological aggregates, P56S-VAPB inclusions in transfected cells correspond to dramatically restructured ER domains. These form after normal integration of the newly synthesized mutant protein into the ER membrane (Fasana et al., 2010). Unlike the multilamellar structures of classical Organized Smooth ER (OSER; Snapp et al., 2003), the ER subdomains in which these aggregates reside consist in a limited number (generally two or three) of undulating cisternae separated by a ~30 nm-
wide electron-dense layer of cytosol (Figure 4(c) to (e); Fasana et al., 2010; Papiani et al., 2012). In agreement with these EM studies, proteomic analysis of immuno-isolated cellular subfractions, as well as in situ proximity ligation assays recently demonstrated the delocalization of mutant VAPB from regions of tubular smooth ER (Yamanaka et al., 2020).

Confocal analysis showed the presence of some ER resident proteins within the P56S-VAPB inclusions. Furthermore, GFP, expressed in the cytosol as a soluble protein or anchored to the ER membrane, can move in and out of them (Teuling et al., 2007; Fasana et al., 2010), indicating that the inclusions do not have the compact structure characteristic of some other mutant protein aggregates (Matsumoto et al., 2006), and demonstrating their continuity with the rest of the ER. Like other mutant proteins involved in neurodegeneration, however, aggregated P56S-VAPB is polyubiquitinated, both in transfected mammalian cells (Kanekura et al., 2006; Papiani et al., 2012) and in transgenic animals (Ratnaparkhi et al., 2008; Tsuda et al., 2008; Tudor et al., 2010; Kuijpers et al., 2013a; Larroquette et al., 2015).

An unexpected discovery for us was the ease with which the cell can eliminate the mutant VAPB inclusions (Papiani et al., 2012). In an inducible HeLa cell model, we found that aggregated P56S-VAPB was eliminated with a half-time of ~7 h versus 17 h for the wt protein. Clearance of the inclusions was operated by the proteasome, with no involvement of macroautophagy, and was inhibited by a dominant negative form of p97/VCP, suggesting that this AAA ATPase extracts single P56S-VAPB molecules from the aggregates for delivery to the proteasome (Papiani et al., 2012; Genevini et al., 2014). In agreement with these results, p97/VCP was detected by immunofluorescence associated with mutant VAPB inclusions (Kuijpers et al., 2013a). The observed instability of P56S-VAPB most likely underlies its generally lower steady state levels compared to the wild-type protein both in transfected cultured cells (e.g., Kanehara et al., 2006; Suzuki et al., 2009; Langou et al., 2010) and in transgenic animals (Aliaga et al., 2013; Kuijpers et al., 2013a; Qiu et al., 2013).

The precise structural modifications that underlie the aggregation propensity of the P56S-VAPB MSP have

---

**Figure 4.** Characterisation of inclusions formed by P56S-VAPB. (A) Immunofluorescence of HeLa cell expressing wt or P56S-VAPB. (B and C) Transmission electron micrographs of HeLa cells transiently transfected with wt (B) or P56S-VAPB (C). N, nucleus, M, mitochondrion; the arrows in (B) indicate normal ER cisternae. (D) High magnification view of altered ER induced by P56S-VAPB. The asterisks mark the ER lumen and the arrows indicate the continuity of the electron dense layer between the cisternae with the surrounding cytosol. The five small arrowheads indicate membrane-attached ribosomes. (E) Tomographic 3D reconstruction of P56S-VAPB inclusion in transfected HeLa cell, confirming the presence of ER cisternae in the structures. Panels (A) to (D): modified from (Fasana et al., 2010), panel (E) is from (Papiani et al., 2012). Scale bars: (A), 5 μm; (B) and (C), 1 μm; (D) and (E), 200 nm.
not been entirely clarified. As shown in Figure 1(b) and (c), Pro56 lies in a highly conserved region of the MSP domain, next to the FFAT peptide binding domain; within this region it adopts the cis-peptide bond conformation, which appears to be required for stabilization of the S-shaped loop that connects the D1 and D2 β strands (Kaiser et al., 2005). Arg55 within the loop and Val54 of the D1 strand directly contact FFAT residues (Furuita et al., 2010; Shi et al., 2010). It might be predicted that substitution of Pro with Ser, which is expected to adopt the energetically more favourable trans-peptide bond conformation, would destabilize the functional conformation, however, there are only few studies to directly assess the structural changes caused by the P56S substitution. NMR and far UV-CD analysis of bacterially expressed P56S-VAPB MSP extracted from inclusion bodies revealed a predominant random-coil conformation of mutant MSP in aqueous solution (Shi et al., 2010), and adoption of an alpha helical conformation in the presence of lipids (Qin et al., 2013). Results of another study, instead, indicated that the mutation has no severe impact on the fold of recombinant MSP, but that solvent-exposed hydrophobic patches on the surface of the mutant drive its temperature-dependent aggregation (Kim et al., 2010). The reported temperature-dependence is consistent with the observation that the mutant drive its temperature-dependent aggregation, however, there are only few studies to directly assess the structural changes caused by the P56S substitution. NMR and far UV-CD analysis of bacterially expressed P56S-VAPB MSP extracted from inclusion bodies revealed a predominant random-coil conformation of mutant MSP in aqueous solution (Shi et al., 2010), and adoption of an alpha helical conformation in the presence of lipids (Qin et al., 2013). Results of another study, instead, indicated that the mutation has no severe impact on the fold of recombinant MSP, but that solvent-exposed hydrophobic patches on the surface of the mutant drive its temperature-dependent aggregation (Kim et al., 2010). The reported temperature-dependence is consistent with the observation that the mutant is largely non-aggregated when expressed in mammalian cells at 20°C (Teuling et al., 2007). The conclusion that the mutation does not cause gross structural changes was reached also for the P56S-VAPA MSP (Furuita et al., 2010).

Relatively mild conformational alterations induced by the P56S substitution would also be consistent with the capability of the mutant MSP, under conditions in which it is not aggregated, to bind FFAT-bearing proteins (Furuita et al., 2010; Kim et al., 2010; Baron et al., 2014). This may explain why the co-expression of mutant VAPB with an FFAT-bearing construct rescues the inclusion phenotype in mammalian cells (Prosser et al., 2008); it may also underlie the surprising observation that mutant VAP (either human VAPB or the Drosophila orthologue VAP33A) rescues lethality and other milder phenotypic effects caused by VAP deletion in flies (Chai et al., 2008; Moustaqim-Barrette et al., 2014; Kamemura et al., 2021). Nevertheless, mutant VAPB within aggregates is unable to interact, or interacts poorly, with the FFAT motif (Teuling et al., 2007; Suzuki et al., 2009; Kim et al., 2010; Kuijpers et al., 2013a); in agreement, the recent study of two of us showed that the P56S substitution caused VAP to lose interactions with multiple partners, including ones that mediate contacts with other organelles in mammalian cells (Yamanaka et al., 2020). Furthermore, in yeast and in zebrafish the mutant protein, unlike in flies, is unable to compensate for VAP loss (Suzuki et al., 2009; Kabashi et al., 2013). These results support the conclusion that the mutation, by driving the aggregation of P56S-VAPB, de facto generates a non-functional protein.

**Are P56S-VAPB Inclusions Pathogenic?**

**Evidence for Gain-of-Function**

The discovery and characterization of P56S-VAPB-containing aggregates led, not surprisingly, to the hypothesis that the aggregates could harm cells by sequestering, through aberrant interactions, wt VAP expressed from the normal allele (negative dominance - Figure 3) and/or other proteins (gain-of-function). Indeed, despite loss of binding to many of its partners (Yamanaka et al., 2020), proteomic analysis has shown that P56S-VAPB retains or shows even increased binding to some of its normal interactors (Huttlin et al., 2015). Accordingly, a number of proteins described in “The VAPs: Structure and Functions” section of this review have been observed to accumulate in P56S-VAPB inclusions: (i) recruitment of Yif1A to VAPB inclusions in transfected mammalian cells results in inhibition of dendritic and axonal growth and maintenance (Kuijpers et al., 2013b); (ii) sequestration by the aggregates of the PI4P phosphatase Sac1 is paralleled by increased PI4P levels in transgenic fly tissues and by consequent neurodegeneration (Forrest et al., 2013)); Recruitment of transfected GFP-Sac1 to P56S-VAPB aggregates has also been observed in mammalian cells (Darbyson and Ngsee, 2016); (iii) the outer mitochondrial membrane protein PTPIP51 drives clustering of mitochondria near the aggregates in cultured cells that strongly overexpress the mutant, in parallel with perturbed Ca2+ handling (De Vos et al., 2012); (iv) similarly, the peroxisomal membrane protein ACBD5 mediates recruitment of peroxisomes to aggregated P56S-VAPB (Hua et al., 2017); (v) the HCN2 channel is trapped in P56S-VAPB aggregates in the cell body of transfected primary cultured cortical neurons and consequently hindered from reaching its normal localization on the cell surface (Silbernagel et al., 2018).

Other proteins reported to accumulate in the inclusions are autophagy and ER stress markers (Tsuda et al., 2008; Aliaga et al., 2013; Larroquette et al., 2015), as well as proteins of the ERAD pathway (Kuijpers et al., 2013a), indicative of disturbed proteostasis and pathological chronic ER stress. In two transgenic mouse lines, the neuronal levels of the ubiquitin-binding autophagy receptor p62/sequestosome are increased (Aliaga et al., 2013; Larroquette et al., 2015), suggesting that alterations in autophagic flux, induced by mutant VAPB, might contribute to neurodegeneration.
Evidence for Negative Dominance

There is ample evidence that P56S-VAPB aggregates are able to sequester the wt protein. Indeed, both in transfected cultured mammalian cells (Kanekura et al., 2006; Teuling et al., 2007; Suzuki et al., 2009; Kim et al., 2010), and in tissues of transgenic flies (Chai et al., 2008; Ratnaparkhi et al., 2008; Tsuda et al., 2008), wt VAPB is recovered within Triton-insoluble P56S-VAPB aggregates and/or is enriched in the inclusions observed by immunofluorescence. The TM domain of wt VAPB is necessary and sufficient for its sequestration (Teuling et al., 2007; Suzuki et al., 2009), but the affinity of the binding is increased by interactions between the wt and the mutant MSPs (Suzuki et al., 2009). In contrast to VAPB, and perhaps surprisingly, given the high degree of sequence conservation between the two VAP paralogues and their capacity to engage in heterodimerization, VAPA is only weakly recruited into the inclusions, if at all (Kanekura et al., 2006; Teuling et al., 2007; Suzuki et al., 2009; Qiu et al., 2013; Yamanaka et al., 2020).

The negative dominance hypothesis has been strengthened by results with animal models, showing that the phenotypic consequences of VAPB (or Drosophila VAP33) deletion are the same as those of mutant VAPB overexpression in a wt background. This is illustrated by the studies on the organization of the neuromuscular junction (NMJ) in the fly model: VAP33 null or hypomorphic mutants and transgenic animals with overexpressed P58S-VAP33 (equivalent to the P56S substitution in humans) in a wt background have a similar phenotype, consisting in a decreased number of synaptic boutons and an increase in their size (Pennetta et al., 2002; Chai et al., 2008; Ratnaparkhi et al., 2008; Forrest et al., 2013) (see Table 2). In addition, P58S-VAP33 overexpression or VAP33 silencing both result in decreased Sca1 activity and increased PI4P levels in MNs (see “The VAPs: Structure and Functions” section; Forrest et al., 2013).

Evidence in Favour of Haploinsufficiency

Despite the above summarized results in support of a pathogenic role of P56S-VAPB, we argue that the p.P56S mutation is unlikely to play a major direct role in ALS pathogenesis either by gain-of-function or by dominant negative loss-of-function mechanisms.

The first, obvious, consideration is that the majority of the studies on the effects of P56S-VAPB inclusions, summarized in Table 2, were carried out in models with expression levels of the mutant well over those supported by one mutant allele as in ALS8 patients. In the one study in Drosophila, in which mutant and wt VAP33 were co-expressed at levels close to the physiological one, no motor deficit, nor neurodegeneration, nor changes in longevity of adult flies were observed (Moustaqim-Barrette et al., 2014). Furthermore, how the effects of mutant VAP on NMJ structure of flies relate to MND is not clear, as overexpression of wt VAP also causes motor dysfunction in adult flies (Tsuda et al., 2008; Sanhueza et al., 2014).

Considering the murine models, of the four reported p.P56S-VAPB transgenic mouse lines, only one, in which the mutant protein was highly overexpressed, developed mild motor abnormalities and loss of cortical, but not spinal, MNs (Aliaga et al., 2013). The other three strains, although presenting P56S-VAPB-containing inclusions in MNs, showed no motor abnormalities (see Table 2).

ALS8 patients’ cells have also been analysed for the presence of inclusions, which were, however, not detected either in MNs generated from induced pluripotent stem cells (iPSCs) from Brazilian subjects (Mitne-Neto et al., 2011) or in skin fibroblasts from a North American patient (Guber et al., 2018). In the Brazilian study, immunoblotting with an antibody that recognizes both the wt and the mutant protein revealed reduced levels (~50% of controls) of VAPB, suggesting that the product of the mutant allele is unstable and eliminated, in agreement with our studies in cultured cells (Papiani et al., 2012; Genevini et al., 2014).

It might be hypothesized that the lack of pathogenicity of the inclusions in transgenic mice is due to differences in metabolism and lifespan between mice and men; however, the results obtained with knock-in mice argue against this idea: the heterozygote knock-in mice developed mild, late onset motor deficits and partial denervation of lower MNs, consistent with the slow progression of ALS8 (Larroquette et al., 2015). Comparison of these results with those of the transgenic animals, in which the full dose of wt VAPB is present, argues strongly in favour of the concept that halving the gene dosage of wt VAPB is necessary to drive ALS8 pathology.

If haploinsufficiency, rather than P56S-VAPB expression, is the main disease-causing mechanism, one should expect that a VAPB knockout heterozygote is equivalent to the p.P56S-VAPB heterozygote knock-in animal. Although VAPB knockout homozygote mice did develop a very mild, but significant, deficit in the rotarod test (Kabashi et al., 2013), the performance of the heterozygotes in this test, although slightly impaired, was not reduced in a statistically significant manner. The better motor performance of the heterozygote knock-out than the heterozygote knock-in mice suggests that the expression of P56S-VAPB does contribute to the disease. However, a study aimed at directly comparing the knockout and knock-in animals has not, to our knowledge, been performed.

In summary, the poor correlation between the presence of P56S-VAPB aggregates and motor dysfunction...
Table 2. Animal Models and Patient Studies on the Consequences of VAPB Depletion or of P56S-VAPB Expression.

| Animal model or patients | Presence of P56S-VAPB inclusions | Tissue/cells analyzed | Motor phenotype/ neurodegeneration | Other | References |
|--------------------------|----------------------------------|----------------------|------------------------------------|-------|------------|
| ALS8 patients            | No                               | Other                | Lower levels of total VAPB in patients' cells | Motor deficit is the defining clinical symptom of the disease | Mitne-Neto et al., 2011 |
| Transgenic mouse         | Yes                              | Spinal cord motor neurons and brain cortex | Induction of TAR-DNA-Binding protein-43 pathology | No overt motor phenotype; no loss of motor neurons. | Tudor et al., 2010 |
| Transgenic mouse         | Yes                              | Spinal cord          | ER stress                          | No motor deficit or neurodegeneration | Qiu et al., 2013 |
| (nervous system-restricted) | Spinal and corticospinal neurons | Yes                   | -                                  | Significant alterations in some motor performance tests and electrophysiological assays; loss of cortical, not spinal, motor neurons | Aliaga et al., 2013 |
| VAPB knock-out mouse     | -                                | -                    | ER stress                          | No motor pathology in 44 out of 46 mice | Kuijpers et al., 2013a |
| P56S-VAPB knock-in mouse | Yesb                            | Lower spinal motor neurons | Alterations in NMJ morphology (number and size of boutons); alterations in phosphoinositol metabolism | Mild, late onset motor deficit; mild partial denervation of lower motor neurons | Larroquette et al., 2015 |
| Transgenic flies         | Yes                              | Larval nerve fibers, brain, neuromuscular junctions | Alterations in NMJ morphology (number and size of boutons) | Locomotion deficit, neuronal apoptosis, muscle wasting | Chai et al., 2008 |
|                         | Yes                              | Larval muscle and neurons | Alterations in NMJ morphology (size of boutons); interference with BMP signaling at the NMJ | Alterations in NMJ morphology (number and size of boutons); alterations in phosphoinositol metabolism | Ratnaparkhi et al., 2008 |
|                         | Yes                              | Motor neurons; wing disc cells | No effect on NMJ morphology | Very mild impairment of flight ability | Tsuda et al., 2008 |
|                         | Not reported                     | Neurons              | No pathology                       | No pathology | Moustaqim-Barrette et al., 2014 |
|                         | Yes                              |                       | Alterations in NMJ morphology (number and size of boutons); alterations in phosphoinositol metabolism | Neurodegeneration in the eye (following targeted expression of transgene) | Forrest et al., 2013 |

(continued)
Table 2. Continued.

| Animal model or patients | Presence of P56S-VAPB inclusions | Tissue/cells analyzed | Yes/no | Other | Motor phenotype/ neurodegeneration | References |
|--------------------------|----------------------------------|-----------------------|--------|-------|------------------------------------|------------|
|                          |                                  |                       |        |       |                                    |            |
| Olfactory projection neurons | Not reported | Mislocalization of presynaptic proteins; induction of UPR |        |       |                                    | Kamemura et al., 2021 |
| Zebrafish (P56S-VAPB mRNA-injected) | - | - | - | No developmental or motor abnormalities in comparison with wt mRNA injected animals | Kabashi et al., 2013 |
| Zebrafish embryos VAPB knockdown | - | - | Bradycardia | Swimming deficits | Kabashi et al., 2013; Silbernagel et al., 2018 |
| Transgenic C. elegans | Wt or P56S-VAPB overexpressed in dorsal A neurons cause backward locomotion defects and premature neuronal death. |        |        |        | Zhang et al., 2017 |

The knock-out animals included in this table are relevant to effects specific for VAPB deletion alone. Knock-out fly and worm lines are not listed, because these organisms harbour a single VAP homolog; hence its deletion is equivalent to the double knockout of the two VAP isoforms in mammals. To be noted, VAPA knockout in mice is embryonic lethal (McCune et al., 2017).

Inclusions are positive for autophagy, and not ER, markers.

The table reports only the results obtained with transgenic flies, in which mutant VAP was expressed in the presence of the wt protein; results were different when the mutant was expressed in a null background (see text).

In this study, mutant and wt VAP were co-expressed at similar, physiological, levels.
in transgenic animals and in patients, and the development, instead, of pathology in heterozygote knock-in animals support the conclusion that the reduced expression of the functional protein driven by a single allele is required to cause MN disease, as previously suggested by us (Papiani et al., 2012; Genevini et al., 2014) and others (Mitne-Neto et al., 2011; Qiu et al., 2013). It cannot, however, be excluded that P56S-VAPB aggre-gates, despite not being detected in patients’ fibroblasts or iPSC-derived MNs, do accumulate to some extent in aged ALS8 MNs, thereby aggravating VAPB haploinsufficiency. A harmful effect of the p.P56S mutation is further suggested by the lack of detection, so far, of loss-of-function mutations of VAPB, not involving the generation of an aggregate-prone protein, in ALS8 patients. Such mutations (e.g., early truncations or frameshift mutations) would strongly support the “pure” haploinsufficiency hypothesis. Future work on animals, cells, and patients will likely resolve the issue of whether haploinsufficiency alone or haploinsufficiency aggravated by the p.P56S mutation drives fALS8 pathology.

**Loss of VAPB Function: What Function?**

Given the extraordinarily large number of vital processes in which the VAPs are involved (“The VAPs: Structure and Functions” section) it is impossible to predict which of these could be impaired in MNs by VAPB deficit. Most likely, more than one process is affected, and the summation of the resulting deficits drives MNs to their demise. In agreement with a pleiotropic effect of VAPB loss, a number of different processes have been reported to be affected in cellular or animal models of VAPB deficiency.

In this section, we will summarize the results of exclusive VAPB deletion/reduction in cellular or animal models; we will not discuss the effects of overexpressed mutant VAPB, nor those of combined VAPA/B knockdown or of VAP deletion/reduction in animals that harbour only one VAP isoform. Whist the dramatic phenotypes observed as a result of total VAP depletion have yielded important mechanistic information on VAP function, we focus here on specific effects of VAPB downregulation as more directly relevant to ALS8 pathogenesis.

**ER-Mitochondria Contact Sites, Ca\(^{2+}\) Regulation, Autophagy**

Silencing of VAPB in the MN-like NSC34 cell line reduces the extension of mitochondria-ER close contacts by 30-40%, and results in a delay in the uptake of cytosolic Ca\(^{2+}\) by mitochondria upon the stimulated release of the cation from ER stores (De Vos et al., 2012; Stoica et al., 2014). The loss of contacts is attributed to the deletion of the VAPB-PTPIP5 tether (“The VAPs: Structure and Functions” section), as VAPB or PTPIP51 silencing produce superimposable effects. Considering that multiple protein complexes are responsible for tethering mitochondria to the ER (Zung and Schuldiner, 2020), the 40% decrease in contact extension obtained by VAPB knockdown is a dramatic effect, implicating the VAPB-PTPIP51 interaction as a prominent contributor to ER-mitochondria contacts. Importantly, such VAPB-PTPIP5-mediated contacts are present also in nerve terminals, and VAPB or PTPIP51 silencing in primary hippocampal neuron cultures reduces ER-mitochondria contacts concomitantly with synaptic activity (Gomez-Suaga et al., 2019).

Another consequence of VAPB silencing, directly linked to the reduction of ER-mitochondria contacts and to impaired Ca\(^{2+}\) regulation, is an increase of basal autophagy and autophagic flux, an effect that can be reversed by expression of an artificial ER-mitochondrion tether in VAPB-silenced cells (Gomez-Suaga et al., 2017). Since autophagy deregulation is implicated in ALS pathogenesis (Navone et al., 2015; Deng et al., 2017), this observation provides a further possible connection between VAPB deficit and MN degeneration.

**HCN Channels**

The discovery of the interaction of the VAPs with HCN1 and 2 channels (“The VAPs: Structure and Functions” section), prompted investigation of the electrophysiological modifications in the heart and in the ventrobasal thalamus of VAPB knockout mice (Silbernagel et al., 2018). In slice patch-clamp experiments, a reduction in the amplitude of the hyperpolarization-induced cation-mediated current characteristic of HCN channels was observed in the neurons of the ventrobasal thalamus of VAPB knock-out mice in comparison to controls. Severe bradycardia, more difficult to relate to ALS, were also observed in the knockout mice. The decreased current amplitude observed in neurons was consistent with decreased surface expression of the HCN1 and 2 channels, a phenomenon attributed to the facilitatory effect of VAPB on transport of the channel through the secretory pathway. As noted in “The VAPs: Structure and Functions” section, the interaction with HCN1 and 2 is mediated by VAPB’s TM helix, and therefore occurs within the plane of the bilayer, a finding difficult to reconcile with the different localisations (ER and plasma membrane) of the interacting proteins. The authors suggest that VAPB is a subunit of HCN channel complexes, however, this hypothesis awaits rigorous proof. The finding that VAPB deletion induces changes in neuronal excitability provides a potential link to ALS8 pathogenesis, of particular interest in light of the implication of
ion channel dysfunction in other neurodegenerative diseases (Chang et al., 2019).

**Dysregulation of Phosphoinositide Metabolism**

A general finding of the past decade has been that VAP depletion causes elevation of intracellular PI4P levels; this phenomenon is observed also in cells with exclusive VAPB knockdown and intact VAPA levels (Darbyson and Ngsee, 2016; Genevini et al., 2019), demonstrating a critical role of VAPB in preserving phosphoinositide homeostasis. Interestingly, in the MN-like NSC34 cell line, even a partial reduction of VAPB, to levels mimicking those of a p.P56S-VAPB heterozygote, is sufficient to affect PI4P levels in the Golgi complex and to cause the expansion of a PI4P-positive population of peripheral vesicles (Genevini et al., 2019). Increased levels of PI4P have been directly linked to neurodegeneration in *Drosophila* and *C. elegans* ALS8 models, in which downregulation or pharmacological inhibition of PI4 kinases, the enzymes that generate PI4P from PI, improves neuronal survival (Forrest et al., 2013; Zhang et al., 2017).

There are several plausible mechanisms that could underlie the neurotoxic effect of elevated PI4P. High levels of the phosphoinositide could excessively or aberrantly recruit PI4P-binding proteins to compartments of the exo-endocytic pathway (De Matteis et al., 2013; Dong et al., 2016; Tan and Gleeson, 2019) or might be linked to disturbances in the distribution of other lipids, whose transport is coupled to that of PI4P. Such alterations could result in impairment of lysosomal degradation and autophagy, as reported by two recent studies (Mao et al., 2019; Zhang et al., 2020) and/or in a deficit in exocytic transport in neurons. Indeed, in the case of the NSC34 cell model, a significantly reduced rate of neurite elongation was observed in VAPB-downregulated cells induced to differentiate (Genevini et al., 2019), suggesting a defect in the trafficking of transport vesicles to the growing neurite; this deficit could as well be relevant to the ability of mature MNs to replenish their axons and dendrites with membrane components. A causal relationship between delayed neuritogenesis and elevated PI4P in the NSC34 model was indicated by the rescue of the phenotype when PI4P levels were reduced by pharmacological inhibition of PI4 kinase IIIβ.

Another contributor to PI4P-induced neurodegeneration could be the disruption of the transport of nuclear envelope and pore proteins to their correct destination, in parallel with nuclear envelope abnormalities, observed as a consequence of VAPB depletion and PI4P elevation (Tran et al., 2012; Darbyson and Ngsee, 2016). These abnormalities could negatively affect nucleocytoplasmic transport, a phenomenon implicated in ALS pathogenesis (Kim and Taylor, 2017), and observed in cultured fibroblasts of an ALS8 patient (Guber et al., 2018).

An open question is the identity of the VAPB-sensitive step(s) within the complex cycle of events that regulate PI4P intracellular levels. Two key players of the cycle are OSBP, which transports PI4P, generated in the Golgi by PI4 kinases, to the ER in exchange for cholesterol, and the phosphatase Sac1, which hydrolyses PI4P in the ER, thus maintaining a Golgi-ER concentration gradient of the phosphoinositide that fuels the OSBP-mediated cholesterol transport out of the ER against its concentration gradient (reviewed in (Antonny et al., 2018)). Sac1 can also act in trans to locally hydrolyse PI4P in the Trans Golgi Network (Venditti et al., 2019). Both OSBP and Sac1 are VAP-dependent (see “The VAPs: Structure and Functions” section), however, OSBP associates with both VAP paralogues (Huttlin et al., 2015; Murphy and Levine, 2016; Cabukusta et al., 2020), and Sac1 has a strong preference for VAPA over VAPB (Wakana et al., 2015). Thus, it is unclear whether either OSBP or Sac1 are affected by the selective downregulation of VAPB, or whether other VAPB-dependent proteins are involved in generating the phosphoinositide imbalance (Darbyson and Ngsee, 2016). The problem of the contribution of VAPB to global VAP (A+B) function will be further discussed in “Why Motor Neurons and Why VAPB?” section.

**ER Stress**

Although indicators of the Unfolded Protein Response (UPR) have been reported to be upregulated in some p. P56S-VAPB transgenic animals (Tsuda et al., 2008; Aliaga et al., 2013), there is relatively little information on the effects of the reduction of endogenous VAPB on ER stress. ER stress takes stage when the protective (adaptive) UPR fails to resolve problems due to excessive load on the ER; chronic ER stress (or maladaptive UPR) can drive cells into apoptosis, hence its involvement in degenerative diseases (Lindholm et al., 2017), including ALS (Kikuchi et al., 2006; Nagata et al., 2007; Saxena et al., 2009).

Kanekura et al. (Kanekura et al., 2006) investigated the role of VAPB in one of the three branches of the UPR, the Ire1-XBP1 axis, which mediates the upregulation of ER chaperones and ERAD (Ron and Walter, 2007). This pathway was blunted in VAPB-silenced NSC34 cells treated with ER stressors, suggesting a role of VAPB in its activation. In another study (Gkogkas et al., 2008), instead, VAPB depletion resulted in increased expression of a UPR reporter under the control of two of the three UPR branches (the transcription factors XBP1 and ATF6), suggesting a role for VAPB in limiting the UPR, a role that was attributed
to the direct interaction between VAPB and ATF6. It is noteworthy, however, that in the spinal cord and tibialis anterior muscle of a knockout mouse model, no alterations of any of the transcriptional readouts for the UPR (the master regulator BiP, and the transcription factors ATF4, ATF6, and CHOP) were detected (Kabashi et al., 2013).

A stronger argument for the involvement of ER stress in the development of ALS8 derives from the work on the knock-in mouse model (Larroquette et al., 2015). Before onset of motor symptoms, the homozygous knock-in mouse showed increased levels of BiP and of protein disulfide isomerase, which both report on an activated UPR. The authors hypothesized that the observed ER stress could be a consequence of deregulated autophagy, as the autophagy receptor p62/SQSTM was upregulated and accumulated in VAPB-containing foci in the MNs of these animals. The two UPR reporters were not, however, increased in heterozygous, age-matched, knock-in mice, which are of greater direct relevance to ALS8. Instead, and interestingly, a significant increase in the phosphorylation of the translation initiation factor eIF2 was observed in the spinal cord of these heterozygotes. Phosphorylation of eIF2α is the direct consequence of activation of the third UPR branch, mediated by the PKR-like ER kinase (PERK), which plays a key role in the maladaptive UPR. Although there was no increase in the expression of the transcription factors (CHOP and ATF4) involved in the PERK-triggered apoptotic pathway, the possibility that this pathway is upregulated in ALS8 is supported also by studies on patient-derived cultured fibroblasts (Guber et al., 2018).

In summary, UPR induction as a direct consequence of VAPB loss is, at present, poorly supported. However, it is feasible that ER stress occurs as an indirect consequence of the VAPB deficit-driven impairment of other processes (“ER-Mitochondria Contact Sites, Ca2+ Regulation, Autophagy,” “HCN Channels,” and “Dysregulation of Phosphoinositide Metabolism” sections) combined with the expression of the P56S mutant from a single allele. Such chronic ER stress could, in the long run, contribute to the deterioration of MN health.

**Why Motor Neurons and Why VAPB?**

A poignant question that concerns many genetic diseases is why only one or a few cell populations are harmed by the mutation of a ubiquitously expressed gene. In the case of VAPB, the question is particularly relevant, because, based on the proteomic analysis of VAP interactors, one might anticipate that the functions of VAPB are largely redundant with those of VAPA, so that loss of function of VAPB might be compensated by the A parologue. The more so, because in all analysed tissues, including spinal cord, VAPA is expressed at higher levels than VAPB, both at the mRNA and at the protein level (www.genecards.org; www.ebi.ac.uk/gxa; www.gtexportal.org).

The vulnerability of MNs to VAPB loss of function has been attributed to the relatively elevated concentration of VAPB in spinal cord homogenates (Teuling et al., 2007); among spinal cord cells, particularly high levels are observed in MNs (Teuling et al., 2007; Larroquette et al., 2015). However, this reasoning does not take into account that also VAPA levels are high in spinal cord, where, like elsewhere, there is more VAPA than VAPB. To be noted, unlike the case of VAPB, VAPA knockout is embryonic lethal in mice (McCune et al., 2017).

In MN-like NSC34 cells, direct comparison of VAPA and VAPB protein levels by quantitative immunoblotting of cell lysates in parallel with standard recombinant proteins revealed an over 4-fold excess of VAPA over B (Genevini et al., 2019). On this basis, complete depletion of VAPB is expected to produce a mere 20% reduction of the global VAP pool. Nonetheless, even partial (50-60%) silencing of VAPB in these cells produced significant phenotypic effects (described in “Loss of VAPB Function: What Function?” section). It seems unlikely that these effects were due to a generalized diminution of the global VAP (A+B) pool: this would imply that the pool operates at levels so close to threshold that even a minor reduction in its levels is poorly tolerated. Instead, it seems more plausible that some specific function(s) of VAPB, which cannot be carried out by VAPA and which are particularly important for MN health and survival, underlie the effects of its depletion.

As noted above, because of the high conservation of the sequences of the two VAP isoforms, particularly of the structurally similar MSP domains, and in view of the results of proteomic analyses showing widely overlapping interaction profiles (e.g., Cabukusta et al., 2020), the two isoforms are considered to share most of their binding partners and to regulate common biological pathways. Nevertheless, as mentioned in previous sections of this review, two binding partners are described to interact more strongly with VAPA than with VAPB; one of these, protrudin (Saita et al., 2009), is a FFAT-bearing protein, while the other one, the Scrl phosphatase, interacts with VAP’s TM helix (Forrest et al., 2013). The converse situation has not been demonstrated so far: while 2-Hybrid screening has identified VAPB as binding partner of PTPIP51 (De Vos et al., 2012) and of HCN1 and 2 (Silbernagel et al., 2018), interactome studies identify also VAPA and MOSPD1-3 as PTPIP51 interactors (Huttlin et al., 2015; Cabukusta et al., 2020); furthermore, PTPIP51 as well as HCN2 are pulled down by both VAP paralogues.
Further differences between the two isoforms are suggested by different effects of overexpression of the wt VAPA or B on secretory pathway function (Prosser et al., 2008) and by the different effect that the P56S substitution has on their structure: introduction of the p. P56S mutation in the VAPA gene does not drive the dramatic aggregation of the overexpressed protein product, as is the case for VAPB (Teuling et al., 2007; Prosser et al., 2008). The future elucidation of additional features that distinguish the two paralogues will be key to unravelling the molecular basis of VAPB’s role in ALS.

Conclusions and Outlook
The discovery of VAPB as a gene linked to MND occurred in the same time period in which the VAP proteins and the repertoire of their binding partners were beginning to be characterized. During the following years, research on the pathogenic mechanism of the VAPB mutation(s) proceeded in parallel with advances in the understanding of the functions of the VAP proteins and of their prominent role in the generation of MCSs.

Analysis of the sum of the studies on p.P56S-driven pathology leads to the conclusion that expression of P56S-VAPB is insufficient to cause disease, and that loss of one VAPB wt allele is necessary to trigger pathological changes in MNs. However, it still remains to be elucidated which of the many VAPB functions/binding partners are critical for MN health and survival; a number of very interesting leads will hopefully be further investigated in the coming years.

Because of the involvement of VAPB in MND, many interaction studies have focussed on the B isoform, disregarding a comparison with VAPA, perhaps because there are no known VAPA-linked diseases. Nevertheless, since there is more VAPA than B in MNs, and since the repertoire of binding partners between the two paralogues is largely overlapping, we feel that an important step in the direction of fully elucidating the pathogenic mechanism of VAPB loss will be to identify those interactors that crucially depend on the entire VAP pool or, alternatively, prefer VAPB over the A parologue. The discovery of functions carried out preferentially by VAPB could lead to the identification of the principal culprits of the MN degeneration caused by VAPB loss, and to the development of novel therapeutic approaches.

Understanding the role of VAPB deficit in ALS is relevant not only for this rare fALS, but also for the more common sALS forms. Reduced VAP levels, or reduced accessibility to anti-VAP antibodies, have been observed in the spinal cords of human sALS patients and of a transgenic fALS mouse model expressing a mutant protein not related to VAPB (G93A-SOD1) (Teuling et al., 2007; Anagnostou et al., 2010; Kim et al., 2016; Cadoni et al., 2020). Conversely, highly overexpressed VAPB was found to be protective for MNs in the same fALS mouse model (Kim et al., 2016).

Finally, beyond MNs, the VAPs are relevant to other pathologies: they play a role in infectious diseases, by facilitating the replication of some viruses and by driving formation of MCS between the ER and the inclusion membrane that encloses intracellular bacteria (reviews: (Derré, 2017; Dudas et al., 2021); VAPB (and maybe VAPA - not tested) promotes breast tumour growth (Rao et al., 2012; Jia et al., 2020), stabilizes mutant Cystic Fibrosis Transmembrane Conductance Regulator (Ernst et al., 2016), affects the inflammatory response of cystic fibrosis bronchial cells to pathogens (Rimessi et al., 2020), and regulates cardiac rhythm (Silbernagel et al., 2018). These phenomena further broaden the scope of future research aimed at unraveling the role of VAPB in MN and other disorders.

Acknowledgements
We are grateful to Marianna Leonzino (CNR Neuroscience Institute) for critically reading the manuscript.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Work in the laboratory of NB and FN was supported by Fondazione Regionale per la Ricerca Biomedica (TRANS-ALS grant no. 2015-0023). Work in the laboratory of TY and NN was supported by a Grant-in-Aid from Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan for T.Y. (18H02723, 17KT0131), Takeda Science Foundation, and The Sumitomo Foundation.

ORCID iD
Nica Borgese https://orcid.org/0000-0002-7537-3974

References
Al-Chalabi A, van den Berg LH, Veldink J (2017). Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol 13, 96–104. doi: 10.1038/nrneurol.2016.182
Aliaga L, Lai C, Yu J, Chub N, Shim H, Sun L, Xie C, Yang WJ, Lin X, O’Donovan MJ, Cai H (2013). Amyotrophic lateral sclerosis-related VAPB P56S mutation differentially affects the function and survival of corticospinal and spinal motor neurons. Human Mol Genet 22, 4293–4305. doi: 10.1093/hmg/ddt279
Alpy F, Rousseau A, Schwab Y, Legueux F, Stoll I, Wendling C, Spiegelhalter C, Kessler P, Mathelin C, Rio MC, et al. (2013). STARD3 or STARD3NL and VAP form a novel molecular tether between late endosomes and the ER. J Cell Sci 126, 5500–5512. doi: 10.1242/jcs.139295

Anagnostou G, Akbar MT, Paul P, Angelinetta C, Steiner TJ, de Belleroce J (2010). Vesicle associated membrane protein B (VAPB) is decreased in ALS spinal cord. Neurobiol Aging 31, 969–985. doi: 10.1016/j.neurobiolaging.2008.07.005

Antonny B, Bigay J, Mesmin B (2018). The oxysterol-binding protein cycle: burning off PI(4)P to transport cholesterol. Annu Rev Biochem 87, 809–837. doi: 10.1146/annurev-biochem-061516-044924

Balla T, Gulyas G, Kim YJ, Pemberton J (2020). Phosphoinositides and calcium signaling. A marriage arranged in Er-Pm contact sites. Curr Opin Physiol 17, 149–157. doi: 10.1016/j.cophys.2020.08.007

Barber SC, Mead RJ, Shaw PJ (2006). Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 1762, 1051–1067. doi: 10.1016/j.bbadis.2006.03.008

Baron Y, Pedrioli PG, Tyagi K, Johnson C, Wood NT, Fountaine D, Wightman M, Alexandru G, Budnik V, Pennetta G (2008). hVAPB, the causative gene of a heterogeneous group of motor neuron diseases in humans, is functionally interchangeable with its Drosophila homologue DVAP-33A at the neuromuscular junction. Human Mol Genet 17, 266–280.

Chang X, Wang J, Jiang H, Shi L, Xie J (2019). Hyperpolarization-activated cyclic nucleotide-gated channels: an emerging role in neurodegenerative diseases. Front Mol Neurosci 12, 141. doi: 10.3389/fnmol.2019.00141

Chattopadhyay D, Sengupta S (2014). First evidence of pathogenicity of V234I mutation of hVAPB found in Amyotrophic Lateral Sclerosis. Biochem Biophys Res Commun 448, 108–113. doi: 10.1016/j.bbrc.2014.04.102

Chen HJ, Anagnostou G, Chai A, Withers J, Morris A, Adhikaree J, Pennetta G, de Belleroce JS (2010). Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. J Biol Chem 285, 40266–40281. doi: 10.1074/jbc.M110.161398

Chung CG, Lee H, Lee SB (2018). Mechanisms of protein toxicity in neurodegenerative diseases. Cell Mol Life Sci 75, 3159–3180. doi: 10.1007/s00018-018-2854-4

Cockerot S, Lev S (2021). Mammalian PITPs at the Golgi and ER-Golgi membrane contact sites. Contact 3, 1–14. doi: 10.1177/2515256420964170

Connolly O, Le Gall L, McCluskey C, Spiegelhalter C, Kessler P, Mathelin C, Rio MC, et al. (2020). Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature 449, 62–67. doi: 10.1038/nature06097

Costello JL, Castro IG, Hacker C, Schrader TA, Metz J, Zechuner D, Azadi AS, Godinio LF, Costina V, Findlesen P, et al. (2017). ACBD5 and VAP mediate membrane associations between peroxisomes and the ER. J Cell Biol 216, 331–342. doi: 10.1083/jcb.201607055

D’Angelo G, Polischuk E, Di Tullio G, Santoro M, Di Campili A, Gori A, West G, Bielaws J, Chuang CC, van der Spool AC, et al. (2017). Glycosphingolipid synthesis to regulate calcium homeostasis. Human Mol Genet 17, 5500–5512. doi: 10.1242/jcs.139295

Deng Z, Sheehan P, Chen S, Yue Z (2017). Is amyotrophic lateral sclerosis/frontotemporal dementia an autophagy disease? Mol Neurodegener 12, 90. doi: 10.1186/s13024-017-0232-6

Derr R (2017). Hijacking of membrane contact sites by intracellular bacterial pathogens. Adv Exp Med Biol 997, 211–223. doi: 10.1007/978-981-10-4567-7_16

De Vos KJ, Morotz GM, Stoica R, Tudor EL, Lau KF, Ackerley S, Warley A, Shaw CE, Miller CC (2012). ORP3 rescues the amyotrophic lateral sclerosis-linked mutant VAPB phenotype. Exp Cell Res 318, 18–31. doi: 10.1016/j.yexcr.2016.01.013 S0014-4827(16)30012-X [pii]

De Matteis MA, Wilson C, D’Angelo G (2013). Phosphatidylinositol-4-phosphate: the Golgi and beyond. BioEssays News Rev Mol Cell Dev Biol 35, 612–622. doi: 10.1002/bies.201200180

Di L, Chen H, Da Y, Wang S, Shen XM (2016). Atypical lysosomal dysfunction and calcium homeostasis in ALS. Cell Mol Life Sci 73, 809–837. doi: 10.1007/s00018-016-1311-z

Ding Y, Chen H, Li N, Wang Y, Shen X (2016). Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. J Biol Chem 285, 40266–40281. doi: 10.1074/jbc.M110.161398

Dong C, Hu X, Li Q, Lu X, Wang Z, Wang C, et al. (2017). VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis. Human Mol Genet 21, 1299–1311. doi: 10.1093/hmg/ddr559

Dr瀂 Jian, Wang Y, Shen X, Shen XM (2016). Atypical lysosomal dysfunction and calcium homeostasis in ALS. Cell Mol Life Sci 73, 809–837. doi: 10.1007/s00018-016-1311-z

Dreyfuss G, Maniatis T (1988). VAPB ER-aggregates, a possible new biomarker in ALS pathology. Cells 9, 164. doi: 10.3390/cells9010164

Chad G, Maximino JR, Jorge FMH, Borba FC, Gilio JM, Callegaro D, Lopes CG, Santos SND, Rebelo GNS (2017). Genetic analysis of patients with familial and sporadic amyotrophic lateral sclerosis in a Brazilian Research Center. Amyotrophic Lateral Sclerosis and Frontotemporal Degener 18, 249–255. doi: 10.1080/21678421.2016.1254245

Chai A, Withers J, Koh YH, Parry K, Bao H, Zhang B, Budnik V, Pennetta G (2008). hVAPB, the causative gene of a heterogeneous group of motor neuron diseases in humans, is functionally interchangeable with its Drosophila homologue DVAP-33A at the neuromuscular junction. Human Mol Genet 17, 266–280.
Di Mattia T, Wilhelm LP, Ikhlef S, Wendling C, Spehner D, Nomine Y, Giordano F, Mathelin C, Drin G, Tomasetto C, Alpy F (2018). Identification of MOSPD2, a novel scaffold for endoplasmic reticulum membrane contact sites. EMBO Rep 19, e45453. doi: 10.15252/embr.201745453

Dong R, Saheki Y, Swarup S, Lucast L, Harper JW, De Camilli P (2016). Endosome-ER contacts control actin nucleation and retromer function through VAP-dependent regulation of PI4P. Cell 166, 408–423. doi: 10.1016/j.cell.2016.06.037

Dudas EF, Huynen MA, Lesk AM, Pastore A (2021). Invisible leashes: the tethering VAP proteins from infectious diseases to neurodegeneration. J Biol Chem 296, 100421. doi: 10.1016/j.jbc.2021.100421

Ernst WL, Shome K, Wu CC, Gong X, Frizzell RA, Aridor M (2016). VAMP-associated proteins (VAP) as receptors that couple cystic fibrosis transmembrane conductance regulator (CFTR) proteostasis with lipid homeostasis. J Biol Chem 291, 5206–5220. doi: 10.1074/jbc.M115.692749

Fasana E, Fossati M, Ruggiano A, Brambillasca S, Hoogenraad CC, Navone F, Francolini M, Borgese N (2010). A VAPB mutant linked to amyotrophic lateral sclerosis generates a novel form of organized smooth endoplasmic reticulum. FASEB J 24, 1419–1430. doi: 10.1096/fj.09-147850

Forrest S, Chai A, Sankueza M, Marescotti M, Parry K, Georgiev A, Sahota V, Mendez-Castro R, Pennetta G (2013). Increased levels of phosphoinositides cause neurodegeneration in a Drosophila model of amyotrophic lateral sclerosis. Human Mol Genet 22, 2689–2704. doi: 10.1093/hmg/ddt118

Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, Muller K, Marroquin N, Nordin F, Hubers A, Weydt P, et al. (2015). Haploinsufficiency of TBK1 causes familial amyotrophic lateral sclerosis. Nat Neurosci 18, 631–636. doi: 10.1038/nn.4000

Funke AD, Esser M, Kruttsorgen A, Weis J, Mitne-Neto M, Lazar M, Nishimura AL, Sperfeld AD, Trillenberg P, Senderek J, et al. (2010). The p.P565S mutation in the VAPB gene is not due to a single founder: the first European case. Clin Genet 77, 302–303. doi: 10.1111/j.1399-0004.2009.01319.x

Furuita K, Jee J, Fukuda H, Mishima M, Kojima C (2010). Electrostatic interaction between oxyyster-binding protein and VAMP-associated protein A revealed by NMR and mutagenesis studies. J Biol Chem 285, 12961–12970. doi: 10.1074/jbc.M109.082602

Genevini P, Colombino MN, Venditti R, Marcuzzo S, Colombo SF, Bernasconi P, De Matteis MA, Borgese N, Navone F (2019). VAPB depletion alters neuritogenesis and phosphoinositide balance in motoneuron-like cells: relevance to VAPB-linked amyotrophic lateral sclerosis. J Cell Sci 132, 1. doi: 10.1242/jcs.220061

Genevini P, Papiani G, Ruggiano A, Cantoni L, Navone F, Borgese N (2014). Amyotrophic lateral sclerosis-linked mutant VAPB inclusions do not interfere with protein degradation pathways or intracellular transport in a cultured cell model. PLoS One 9, e113416. doi: 10.1371/journal.pone.0113416

Gkogkas C, Middleton S, Kremer AM, Wardrope C, Hannah M, Gillingwater TH, Skehel P (2008). VAPB interacts with and modulates the activity of ATP6. Human Mol Genet 17, 1517–1526. doi: 10.1093/hmg/ddn040

Gomez-Suaga P, Paillusson S, Stoca R, Noble W, Hanger DP, Miller CCJ (2017). The ER mitochondria tethering complex VAPB-PTPIP51 regulates autophagy. Curr Biol 27, 371–385. doi: 10.1016/j.cub.2016.12.038

Gomez-Suaga P, Perez-Nievas BG, Glennon EB, Lau DHW, Paillusson S, Morotz GM, Cali T, Pizzo P, Noble W, Miller CCJ (2019). The VAPB-PTPIP51 endoplasmic reticulum-mitochondria tethering proteins are present in neuronal synapses and regulate synaptic activity. Acta Neuropathol Commun 7, 35. doi: 10.1186/s40478-019-0688-4

Guber RD, Schindler AB, Budron MS, Chen KL, Li Y, Fischbeck KH, Gruneich C (2018). Nucleocytoplasmic transport defect in a North American patient with ALS8. Ann Clin Transl Neurol 5, 369–375. doi: 10.1002/acn.3.515

Guillen-Samander A, Leonzino M, Hanga MG, Tang N, Shen H, De Camilli P (2021). VPS13D bridges the ER to mitochondria and peroxisomes via Miro. J Cell Biol 220. doi: 10.1083/jcb.202010004

Haass C, Selkoe DJ (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nature Rev Mol Cell Biol 8, 101–112. doi: 10.1038/nrm2101

Hammond GRV, Burke JE (2020). Novel roles of phosphoinositides in signaling, lipid transport, and disease. Curr Opin Cell Biol 63, 57–67. doi: 10.1016/j.cceb.2019.12.007

Han SM, El Oussini H, Seekic-Zahirovic J, Vibbert J, Cottee P, Prasain JK, Bellen HJ, Dupuis L, Miller MA (2013). VAPB/ALS8 MSP ligands regulate striated muscle energy metabolism critical for adult survival in Caenorhabditis elegans. PLoS Genet 9, e1003738. doi: 10.1371/journal.pgen.1003738

Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robertscheid W, Shaw PJ, Simmons Z, van den Berg LH (2017). Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3, 17071. doi: 10.1038/nrdp.2017.71

Hua R, Cheng D, Coyaud E, Freeman S, Di Pietro E, Wang Y, Vissa A, Yip CM, Fairn GD, Braverman N, et al. (2017). VAPs and ACBD5 tether peroxisomes to the ER for peroxisome maintenance and lipid homeostasis. J Cell Biol 216, 367–377. doi: 10.1083/jcb.201608128

Huttlin EL, Ting L, Bruckner RJ, Gbreyab F, Gyi MP, Szpyt J, Tam S, Zarraga G, Colby G, Baltier K, et al. (2015). The BioPlex network: a systematic exploration of the human interactome. Cell 162, 425–440. doi: 10.1016/j.cell.2015.06.043

Jia H, Liang K, Liu G, Zhang Z, Shi Y, Liang H, Liu P (2020). IncRNA DANC5 promotes proliferation and metastasis of breast cancer cells through sponging miR-4319 and upregulating VAPB. Cancer Biother Radiopharm 2020. doi: 10.1089/cbr.2020.3675. Epub ahead of print. PMID: 32818383.

Johnson AF, Nguyen HT, and Veitia RA (2019). Causes and effects of haploinsufficiency. Biological Reviews 94, 1774–1785. doi: 10.1111/brv.12527

Johnson B, Leek AN, Sole L, Maverick EE, Levine TP, Tankum MM (2018). Kv2 potassium channels form endoplasmic reticulum/plasma membrane junctions via...
interaction with VAPA and VAPB. Proc Natl Acad Sci U S A 115, E7331–E7340. doi: 10.1073/pnas.1805757115

Kabashi E, El Oussini H, Bercier V, Gros-Louis F, Valdmannis PN, McDearmid J, Meijer IA, Dion PA, Dupre N, Hollinger D, et al. (2013). Investigating the contribution of VAPB/ALS8 loss of function in amyotrophic lateral sclerosis. Human Mol Genet 22, 2350–2360.

Kaiser SE, Brückner JH, Reilein AR, Fenn TD, Walter P, Brünger AT (2005). Structural basis of FFAT motif-mediated ER targeting. Structure 13, 1035–1045.

Kamemura K, Chen CA, Okumura M, Miura M, Chihara T (2013a). Amyotrophic lateral sclerosis (ALS)-associated protein-interacting FFAT motif of CERT. J Biol Chem 288, 30279–30288. doi: 10.1074/jbc.M605032200

Kawano M, Kumagai K, Nishijima M, Hanada K (2006). Characterization of amyotrophic lateral sclerosis-linked P56S mutation of vesicle-associated membrane protein-associated protein B (VAPB/ALS8). J Biol Chem 281, 30223–30233. doi: 10.1074/jbc.M605049200

Kikuchi H, Almer G, Yamashita S, Guegan C, Nagai M, Xu Z, Sosunov AA, McKhann GM 2nd, Przedborski S (2006). Spinal cord endoplasmic reticulum stress and neuron morphology in Drosophila. Genes Cells 26, 230–239. doi: 10.1111/gtc.12835

Kanekura K, Nishimoto I, Aiso S, Matsuoka M (2006). Characterization of amyotrophic lateral sclerosis-associated VAP33 is required for maintaining neuronal dendrite morphology and organelle distribution in Drosophila. Genes Cells 26, 230–239. doi: 10.1111/gtc.12835

Kaneura K, Nishimoto I, Aiso S, Matsuoka M (2006). Characterization of amyotrophic lateral sclerosis-linked P56S mutation of vesicle-associated membrane protein-associated protein B (VAPB/ALS8). J Biol Chem 281, 30223–30233. doi: 10.1074/jbc.M605049200

Kawano M, Kumagai K, Nishijima M, Hanada K (2006). Effective trafficking of ceramide from the endoplasmic reticulum to the Golgi apparatus requires a VAMP-associated protein-interacting FFAT motif of CERT. J Biol Chem 281, 30279–30288. doi: 10.1074/jbc.M605032200

Kim HJ, Taylor JP (2017). Lost in transportation: nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. Neuron 96, 285–297. doi: 10.1016/j.neuron.2017.07.029

Kim JY, Jang A, Reddy R, Hee Yoon W, Jankowsky JL (2016). Neuronal overexpression of human VAPB slows motor impairment and neuromuscular denervation in a mouse model of ALS. Human Mol Genet 25, 6461–6473. doi: 10.1093/hmg/ddw294

Kim S, Leal SS, Ben Haley D, Gomes CM, Lev S (2010). Structural requirements for VAP-B oligomerization and their implication in amyotrophic lateral sclerosis-associated VAP-B(P56S) neurotoxicity. J Biol Chem 285, 13839–13849. doi: 10.1074/jbc.M109.073435

Kim YJ, Guzman-Hernandez ML, Wisniewski E, Balla T (2015). Phosphatidylinositol-phosphatidic acid exchange by Nir2 at ER-PM contact sites maintains phosphoinositide signaling competence. Dev Cell 33, 549–561. doi: 10.1016/j.devcel.2015.04.028

Kirmiz M, Vierra NC, Palacio S, Trimmer JS (2018). Identification of VAPA and VAPB as Kv2 channel-interacting proteins defining endoplasmic reticulum-plasma membrane junctions in mammalian brain neurons. J Neurosci 38, 7562–7584. doi: 10.1523/JNEUROSCI.0893-18.2018

Kuijpers M, van Dis V, Haasdijk ED, Harterink M, Vocking K, Post JA, Schepers W, Hoogenraad CC, Jaarsma D (2013a). Amyotrophic lateral sclerosis (ALS)-associated VAPB-P56S inclusions represent an ER quality control compartment. Acta Neuropathol Commun 1, 24. doi: 10.1186/2051-5960-1-24

Kuijpers M, Yu KL, Teuling E, Akhmanova A, Jaarsma D, Hoogenraad CC (2013b). The ALS8 protein VAPB interacts with the ER-Golgi recycling protein YIF1A and regulates membrane delivery into dendrites. EMBO J 32, 2056–2072. doi: 10.1038/emboj.2013.131

Kumar N, Leonzino M, Hancock-Cerutti W, Horenkamp FA, Li P, Lees JA, Wheeler H, Reinsch KM, De Camilli P (2018). VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites. J Cell Biol 217, 3625–3639. doi: 10.1083/jcb.201807019

Ladinsky MS, Mastronarde DN, McIntosh JR, Howell KE, Staeelin LA (1999). Golgi structure in three dimensions: functional insights from the normal rat kidney cell. J Cell Biol 144, 1135–1149. doi: 10.1083/jcb.144.6.1135

Landers JE, Leelerc AL, Shi L, Virkud A, Cho T, Maxwell MM, Henry AF, Polak M, Glass JD, Kwiatkowski TJ, et al. (2008). New VAP deletion variant and exclusion of VAPB mutations in familial ALS. Neurology 70, 1179–1185. doi: 10.1212/01.wnl.0000289760.85237.4e

Languo K, Moumen A, Pellegrino C, Aebischer J, Medina I, Aebischer P, Raoul C (2010). AAV-mediated expression of wild-type and ALS-linked mutant VAPB selectively triggers death of motoneurons through a Ca2+–dependent ER-associated pathway. J Neurochem 114, 795–809. doi: 10.1111/j.1471-4159.2010.06806.x

Larroquette F, Seto L, Gauß PL, Kamal B, Wallis D, Lariviere R, Valley J, Robitaille R, Tsuda H (2015). Vapb/ Amyotrophic lateral sclerosis 8 knock-in mice display slowly progressive motor behavior defects accompanying ER stress and autophagic response. Human Mol Genet 24, 6515–6529. doi: 10.1038/hmg/dsv360

Lev S, Ben Haley D, Peretti D, Dahan N (2008). The VAP protein family: from cellular functions to motor neuron disease. Trends Cell Biol 18, 282–290. doi: 10.1016/j.tcb.2008.03.006

Levine TP, Munro S (2002). Targeting of Golgi-specific pleckstrin homology domains involves both PtdIns 4-kinase-dependent and -independent components. Curr Biol 12, 695–704. doi: 10.1016/s0960-9822(02)00779-0

Lim CY, Davis OB, Shin HR, Zhang J, Berdan CA, Jiang X, Cournihan JL, Ory DS, Nomura DK, Zoncu R (2019). ER-lysosome contacts enable cholesterol sensing by mTORC1 and drive aberrant growth signalling in Niemann-Pick type C. Nature Cell Biol 21, 1206–1218. doi: 10.1038/s41556-019-0391-5

Lindholm D, Korhonen L, Eriksson O, Koks S (2017). Recent insights into the role of unfolded protein response in ER stress in health and disease. Front Cell Dev Biol 5, 48. doi: 10.3389/fcell.2017.00048

Lindhout FW, Cao Y, Kevenaar JT, Bodzeta A, Stucchi R, MacGillavry HD, Hoogenraad CC (2019). VAP-SCRN1 interaction regulates dynamic endoplasmic reticulum remodeling and presynaptic function. EMBO J 38, e101345. doi: 10.15252/embj.2018101345
Millecamps S, Salachas F, Cazeneuve C, Gordon P, Bricka B, Mitne-Neto M, Machado-Costa M, Marchetto MC, Bengtson Miller MA, Nguyen VQ, Lee MH, Kosinski M, Schedl T, Mikitova V, Levine TP (2012). Analysis of the key elements of McCune BT, Tang W, Lu J, Eaglesham JB, Thorne L, Mayer Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari Mesmin B, Bigay J, Moser von Filseck J, Lacas-Gervais S, Matsumoto G, Kim S, Morimoto RI (2006). Huntingtin and Mao D, Lin G, Tepe B, Zuo Z, Tan KL, Senturk M, Zhang S, Lunn MR, Wang CH (2008). Spinal muscular atrophy. Lancet Ludwig A, Zong X, Jeglitsch M, Hofmann F, Biel M (1998). A family of hyperpolarization-activated mammalian cation channels. Nature 393, 587–591. doi: 10.1038/31255 Lunn MR, Wang CH (2008). Spinal muscular atrophy. Lancet 371, 2120–2133. doi: 10.1016/S0140-6736(08)60921-6 Mao D, Lin G, Tepe B, Zuo Z, Tan KL, Senturk M, Zhang S, Arenkiel BR, Sardiello M, Bellen HJ (2019). VAMP associated proteins are required for autophagic and lysosomal degradation by promoting a PtdIns4P-mediated endosomal pathway. Autophagy 15, 1214–1233. doi: 10.1080/15548627.2019.1580103

Marques VD, Barreira AA, Davis MB, Abou-Sleiman PM, Silva WA Jr, Zago MA, Sobreira C, Fazan V, Marques W Jr (2006). Expanding the phenotypes of the Pro56Ser VAPB mutation: proximal SMA with dysautonomia. Muscle Nerve 34, 731–739. doi: 10.1002/mus.20657.

Matsumoto G, Kim S, Morimoto RJ (2006). Huntingtin and mutant SOD1 form aggregate structures with distinct molecular properties in human cells. J Biol Chem 281, 4477–4485. doi: 10.1074/jbc.M509201200

McCune BT, Tang W, Lu J, Eaglesham JB, Thorne L, Mayer AE, Condiff E, Nice TJ, Goodfellow I, Krezel AM, Virgin HW (2017). Norroviruses co-opt the function of host proteins VAPA and VAPB for replication via a phenylalanine-phenylalanine-acyclic-tract-motif mimic in nonstructural viral protein NS1/2. mBio 8, e00668-17 doi: 10.1128/mBio.00668-17

Mejizini R, Flynn LL, Pitout IL, Fletcher S, Wilson SD, Akkari PA (2019). ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci 13, 1310. doi: 10.3389/fnins.2019.01310

Mesmin B, Bigay J, Moser von Fileck J, Lacas-Gervais S, Drin G, Antonny B (2013). A four-step cycle driven by PI(4)P hydrolysis directs sterol/PI(4)P exchange by the ER-Golgi tether OSBP. Cell 155, 830–843. doi: 10.1016/j.cell.2013.09.056

Mikitova V, Levine TP (2012). Analysis of the key elements of FFAT-like motifs identifies new proteins that potentially bind VAP on the ER, including two AKAPs and FAPP2. PLoS One 7, e30455. doi: 10.1371/journal.pone.0030455

Millecamps S, Salachas F, Cazeneuve C, Gordon P, Bricka B, Camuzat A, Guilhot-Noel L, Russaouen O, Bruneteau G, Pradat PF, et al. (2010). SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis-associated gene VAPB expressed in human tissues. Biochem Biophys Res Commun 394, 703–708. doi: 10.1016/j.bbrc.2010.03.055

Nagata T, Ilieva H, Murakami T, Shiote M, Narai H, Ohta Y, Hayashi T, Shoji M, Abe K (2007). Increased ER stress during motor neuron degeneration in a transgenic mouse model of amyotrophic lateral sclerosis. Neuronal Res 29, 767–771. doi: 10.1177/016164107X229803

Navone F, Genevini P, Borgese N (2015). Autophagy and neurondegeneration: insights from a cultured cell model of ALS. Cells 4, 354–386. doi: 10.3390/cells04030354

Nishimura AL, Al-Chalabi A, Zatz M (2005). A common founder for amyotrophic lateral sclerosis type 8 (ALS8) in the Brazilian population. Hum Genet 118, 499–500. doi: 10.1007/s00439-005-0031-y

Nishimura AL, Mitne-Neto M, Silva HCA, Oliveira JR, Vainzof M, Zatz M. (2004a). A novel locus for late onset amyotrophic lateral sclerosis/motor neurone disease variant at 2q13. J Med Genet 41, 315–320. doi: 10.1136/jmg.2003.013029

Nishimura AL, Mitne-Neto M, Silva HCA, Richieri-Costa A, Middleton S, Cascio D, Kok F, Oliveira JRM, Gillingwater T, Webb J, et al. (2004b). A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75, 822–831. doi: 10.1086/425287

Nishimura Y, Hayashi M, Inada H, Tanaka T (1999). Molecular cloning and characterization of mammalian homologues of vesicle-associated membrane protein-associated (VAMP-associated) proteins. Biochem Biophys Res Commun 254, 21–26. doi: 10.1006/bbrc.1998.9876

Nthiga TM, Kumar Shrestha B, Sjottet E, Bruun JA, Bowitz Larsen K, Bhujabal Z, Lamark T, Johansen T (2020). CALCOCO1 acts with VAMP-associated proteins to mediate ER-phagy. EMBO J 39, e103649. doi: 10.15252/embj.2019103649

Olzseh H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer-Hartl M, Hartl FU, Vabulas RM (2011). Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67–78. doi: 10.1016/j.cell.2010.11.050
Snapp EL, Hegde RS, Francolini M, Lombardo F, Colombo S, Pedrazzini E, Borgese N, Lippincott-Schwartz J (2003). Formation of stacked ER cisternae by low affinity protein interactions. J Cell Biol 163, 257–269. doi: 10.1083/jcb.200306020

Stefan CJ, Manford AG, Baird D, Yamada-Hanff J, Mao Y, Emr SD (2011). Osh proteins regulate phosphoinositide metabolism at ER-plasma membrane contact sites. Cell 144, 389–401. doi: 10.1016/j.cell.2010.12.034

Stoica R, De Vos KJ, Pailloux S, Mueller S, Sancho RM, Lau KF, Vizcay-Barrena G, Lin WL, Xu YF, Lewis J, et al. (2014). ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nature Commun 5, 3996. doi: 10.1038/ncomms4996

Sun YM, Dong Y, Wang J, Lu JH, Chen Y, Wu JJ (2017). A neuronal loss-of-function mutant of VAPB, predisposes motor neurons to ER stress-related death by inducing aggregation of co-expressed wild-type VAPB. J Neurochem 108, 973–985. doi: 10.1111/j.1471-4159.2008.05857.x

Tan IZA, Gleeson PA (2019). Cargo sorting at the trans-Golgi network for shunting into specific transport routes: role of Arf small G proteins and adapter complexes. Cells 8, 3289-3311. doi: 10.3390/cells8060393

Teuling E, Ahmed S, Haasdijk E, Demmers J, Steinmetz MO, Akhmanova A, Jaarsma D, Hoogenraad CC (2007). Motor neuron disease-associated mutant vesicle-associated membrane protein-associated protein (VAP) B recruits wild-type VAPs into endoplasmic reticulum-derived tubular aggregates. J Neurosci 27, 9801–9815. doi: 10.1523/JNEUROSCI.2661-07.2007

Tran D, Challhoub A, Schooley A, Zhang W, Ngsee JK (2012). A mutation in VAPB that causes amyotrophic lateral sclerosis also causes a neural envelope defect. J Cell Sci 125, 2831–2836. doi: 10.1242/jcs.102111

Tsunoda H, Han SM, Yang Y, Tong C, Lin YQ, Mohan K, Haueter C, Zoghbi A, Harati Y, Kwan J, et al. (2008). The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell 133, 963–977. doi: 10.1016/j.cell.2008.04.039

Tudor EL, Galtrey CM, Perkinton MS, Lau KF, De Vos KJ, Mitchell JC, Ackerley S, Hortalbagyi T, Vamos E, Leigh PN, et al. (2010). Amyotrophic lateral sclerosis mutant vesicle-associated membrane protein-associated protein-B transgenic mice develop TAR-DNA-binding protein-43 pathology. Neuroscience 167, 774–785. doi: 10.1016/j.neuroscience.2010.02.035

van Blitterswijk M, van Es MA, Koppers M, van Rheenen W, Medic J, Schelhaas HJ, van der Koop AJ, de Visser M, Veldink JH, van den Berg LH (2012). VAPB and C9orf72 mutations in 1 familial amyotrophic lateral sclerosis patient. Neurobiol Aging 33, 2950 e2951–2954.e2951. doi: 10.1016/j.neurobiolaging.2012.07.004

Venditti R, Masone MC, Rega LR, Di Tullio G, Santoro M, Polisichuk E, Serrano IC, Ollkken VM, Harada A, Medina DL, et al. (2019). The activity of Sac1 across ER-TGN contact sites requires the four-phosphate-adapter-protein-1. J Cell Biol 218, 783–797. doi: 10.1083/jcb.201812021

Wakana Y, Kotake R, Oyama N, Murate M, Kobayashi T, Arasaki K, Inoue H, Tagaya M (2015). CARTS biogenesis requires VAP-lipid transfer protein complexes functioning at the endoplasmic reticulum-Golgi interface. Mol Biol Cell 26, 4668–4699. doi: 10.1091/mbc.E15-08-0599

Weir ML, Xie H, Klip A, Trimble WS (2001). VAP-A binds promiscuously to both v- and tSNAREs. Biochem Biophys Res Commun 286, 616–621. doi: 10.1006/bbrc.2001.5437

Wijdeven RH, Janssen H, Nahidiazar L, Janssen L, Jaink K, Berlin I, Neefjes J (2016). Cholesterol and ORP1L-mediated ER contact sites control autophagosome transport and fusion with the endocytic pathway. Nature Commun 7, 11808. doi: 10.1038/ncomms11808

Wilkie AOM (1994). The molecular basis of genetic dominance. J Med Genet 31, 89–98. doi: 10.1136/jmg.31.2.89

Wilkinson S (2020). Emerging principles of selective ER autophagy. J Mol Biol 432, 185–205. doi: 10.1016/j.jmb.2019.05.012

Wong LH, Gatta AT, Levine TP (2018). Lipid transfer proteins: the lipid commute via shuttles, bridges and tubes. Nat Rev Mol Cell Biol 20, 85–101. doi: 10.1038/s41598-018-0071-5

Wu D, Hao Z, Ren H, Wang G (2018). Loss of VAPB regulates autophagy in a beclin 1-dependent manner. Neurosci Bull 34, 1037–1046. doi: 10.1007/s12264-018-0276-9

Wyles JP, McMaster CR, Ridgway ND (2002). Vesicle-associated membrane protein-associated protein-A (VAP-A) interacts with the oxysterol-binding protein to modify export from the endoplasmic reticulum. J Biol Chem 277, 29908–29918. doi: 10.1074/jbc.M201191200

Yamanaka T, Nishiyama R, Shimogori T, Nukina N (2020). Proteomics-based approach identifies altered ER domain properties by ALS-linked VAPB mutation. Sci Rep 10, 7610. doi: 10.1038/s41598-020-64517-z

Yeshaw WM, van der Zwaag M, Pinto F, Lahaye LL, Faber AI, Gomez-Sanchez R, Dolga AM, Poland C, Monaco AP, van IS, et al. (2019). Human VPS13A is associated with multiple organelles and influences mitochondrial morphology and lipid droplet motility. eLife 8, e43561. doi: 10.7554/eLife.43561

Zheng H, Zhou J, Xiao P, Lin Y, Gong X, Liu S, Xu Q, Wang M, Ren H, Lu M, Wang Y, Zhu J, Xie Z, Li H & Lu K (2020). PtdIns4P restriction by hydrolase SAC1 decides specific fusion of autophagosomes with lysosomes, Autophagy. doi: 10.1007/s12264-020-0277-9

Zhang W, Colavita A, Ngsee JK (2017). Mitigating motor neuronal loss in C. elegans model of ALS8. Sci Rep 7, 11582. doi: 10.1038/s41598-017-11798-6

Zhao YG, Liu N, Miao G, Chen Y, Zhao H, Zhang H (2018). The ER contact proteins VAPA/B interact with multiple autophagy proteins to modulate autophagosome biogenesis. Curr Biol 28, 1234–1245. doi: 10.1016/j.cub.2018.03.002

Zung N, Schuldiner M (2020). New horizons in mitochondrial contact site research. Biochem Cell 407, 793–809. doi: 10.1515/hsz-2020-0133